Song L, Nakaar V, Kavita U, Price A, Huleatt J, Ta. Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS ONE. 2008 May 21;3(5):e2257
It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.
- Rapid interferon independent expression of IFITM3 following T cell activation protects cells from influenza virus infection 1 days ago
- Recombinant turkey herpesvirus expressing H9 hemagglutinin providing protection against H9N2 avian influenza 3 days ago
- Adjuvanted influenza vaccine dynamics 4 days ago
- MOV10 sequesters the RNP of influenza A virus in the cytoplasm and is antagonized by viral NS1 protein 5 days ago
- Multiple amino acid substitutions involved in the adaption of three avian-origin H7N9 influenza viruses in mice 5 days ago